Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses-MedSci.cn

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Mok, TSK; Kim, SW; Wu, YL; Nakagawa, K; Yang, JJ; Ahn, MJ; Wang, J; Yang, JCH; Lu, Y; Atagi, S; Ponce, S; Shi, XJ; Rukazenkov, Y; Haddad, V; Thress, KS; Soria, JC

Mok, TSK (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, 22D Union Court,18 Fu Kin St, Sha Tin, Hong Kong, Peoples R China.

Abstract

Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

科室

工具

服务